FE Heart Attack
Background: Many constituents of fruits and vegetables may reduce the risk for coronary heart disease, but data on the relationship between fruit and vegetable consumption and risk for coronary heart disease are sparse.
FE Heart Attack
Measurements: The main outcome measure was incidence of nonfatal myocardial infarction or fatal coronary heart disease (1127 cases in women and 1063 cases in men). Diet was assessed by using food-frequency questionnaires.
Results: After adjustment for standard cardiovascular risk factors, persons in the highest quintile of fruit and vegetable intake had a relative risk for coronary heart disease of 0.80 (95% CI, 0.69 to 0.93) compared with those in the lowest quintile of intake. Each 1-serving/d increase in intake of fruits or vegetables was associated with a 4% lower risk for coronary heart disease (relative risk, 0.96 [CI, 0.94 to 0.99]; P = 0.01, test for trend). Green leafy vegetables (relative risk with 1-serving/d increase, 0.77 [CI, 0.64 to 0.93]), and vitamin C-rich fruits and vegetables (relative risk with 1-serving/d increase, 0.94 [CI, 0.88 to 0.99]) contributed most to the apparent protective effect of total fruit and vegetable intake.
Conclusions: Consumption of fruits and vegetables, particularly green leafy vegetables and vitamin C-rich fruits and vegetables, appears to have a protective effect against coronary heart disease.
Iron deficiency (ID) is one of the most frequent comorbidities in patients with heart failure (HF). ID is estimated to be present in up to 50% of outpatients and is a strong independent predictor of HF outcomes. ID has been shown to reduce quality of life, exercise capacity and survival, in both the presence and absence of anemia. The most recent 2016 guidelines recommend starting replacement treatment at ferritin cutoff value
More troublesome bradycardias that cause repeated and prolonged symptoms may need to be treated with a pacemaker. This is an electric device surgically implanted in the chest to help regulate the heartbeat.
Heart failure happens when your heart is unable to effectively pump blood around your body. It can develop after a heart attack if your heart muscle is extensively damaged. This usually happens in the left side of the heart (the left ventricle).
Cardiogenic shock is similar to heart failure, but more serious. It develops when the heart muscle has been damaged so extensively it can no longer pump enough blood to maintain many of the body's functions.
Once the initial symptoms of cardiogenic shock have been stabilised, surgery may be required to improve the functioning of the heart. This may include percutaneous coronary intervention (PCI), alongside the insertion of a small pump, known as an intra-aortic balloon pump. This can help improve the flow of blood from the heart.
Normally, your intestines absorb just the right amount of iron from the food you eat. But with hemochromatosis, the body absorbs extra iron and stores it in your organs, especially your heart, liver and pancreas.
We believe every human being should have access to the information, care and treatment they need to keep their heart healthy, regardless of race, nationality, gender, age, education or income. At the World Heart Federation, we work tirelessly to ensure the global population is provided with accurate and up to date details and data on cardiovascular diseases.
The Heart Hospital of New Mexico at Lovelace Medical Center is the only hospital in New Mexico that is entirely dedicated to heart care. Our skilled team use state-of-the-art technology, offering treatment options for all types of heart and vascular conditions
The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of 153,760 individuals with COVID-19, as well as two sets of control cohorts with 5,637,647 (contemporary controls) and 5,859,411 (historical controls) individuals, to estimate risks and 1-year burdens of a set of pre-specified incident cardiovascular outcomes. We show that, beyond the first 30 d after infection, individuals with COVID-19 are at increased risk of incident cardiovascular disease spanning several categories, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease. These risks and burdens were evident even among individuals who were not hospitalized during the acute phase of the infection and increased in a graded fashion according to the care setting during the acute phase (non-hospitalized, hospitalized and admitted to intensive care). Our results provide evidence that the risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial. Care pathways of those surviving the acute episode of COVID-19 should include attention to cardiovascular health and disease.
People who survived the first 30 d of COVID-19 exhibited increased risk of stroke (hazard ratio (HR) = 1.52 (1.43, 1.62); burden 4.03 (3.32, 4.79) per 1,000 persons at 12 months; for all HRs and burdens, parenthetical ranges refer to 95% confidence intervals (CIs)) and transient ischemic attacks (TIA) (HR = 1.49 (1.37, 1.62); burden 1.84 (1.38, 2.34)). The risks and burdens of a composite of these cerebrovascular outcomes were 1.53 (1.45, 1.61) and 5.48 (4.65, 6.35).
Inflammatory disease of the heart or pericardium included pericarditis (HR = 1.85 (1.61, 2.13)); burden 0.98 (0.70, 1.30) and myocarditis (HR = 5.38 (3.80, 7.59); burden 0.31 (0.20, 0.46)). The risks and burdens of a composite of these inflammatory diseases of the heart or pericardium were 2.02 (1.77, 2.30) and 1.23 (0.93, 1.57).
In summary, using a national cohort of people with COVID-19, we show that risk and 12-month burden of incident cardiovascular disease are substantial and span several cardiovascular disease categories (ischemic and non-ischemic heart disease, dysrhythmias and others). The risks and burdens of cardiovascular disease were evident even among those whose acute COVID-19 did not necessitate hospitalization. Care pathways of people who survived the acute episode of COVID-19 should include attention to cardiovascular health and disease.
In addition to pre-defined covariates, we further algorithmically selected additional potential confounders from data domains, including diagnoses, medications and laboratory tests27. To accomplish this, we gathered all patient encounter, prescription and laboratory data and classified the information into 540 diagnostic categories, 543 medication classes and 62 laboratory test abnormalities. For the diagnoses, medications and laboratory abnormalities that occurred in at least 100 participants within each group, univariate relative risk between the variable and exposure was calculated, and the top 100 variables with the strongest relative risk were selected28. The process of algorithmically selecting the high-dimensional covariates was independently conducted for each outcome-specific cohort in each comparison (for example, the COVID-19 versus contemporary control analyses to examine incident heart failure and the COVID-19 versus historical control analyses to examine incident heart failure).
"People with underlying heart problems can die suddenly due to extreme stress or excitement. This may be due to a plaque rupture in the coronaries or triggering of an arrhythmia due to the excitement," he said.
"After COVID, there is a continuing inflammation in our blood vessels. Because of stress, increase in blood pressure like what happened in this case, arteries of the heart could have ruptured and that can cause sudden cardiac arrest."
Since their introduction, combined oral contraceptive pills have become one of the most popular birth control methods. These pills contain two types of female hormones, estrogen and progestagen. When used correctly, the failure rate (i.e. the occurrence of unwanted pregnancy) is less than one per 100 women per year. Despite their reliability, oral contraceptive pills have been found to increase the risk of a blood clot forming in an artery, i.e. arterial thrombosis (heart attack or stroke). As arterial thrombosis is rare in young women, and as many types of oral contraceptive pills exist, the size of the risk is unclear. Furthermore, the effect of different types of progestagens or different doses of estrogen on the risk of arterial thrombosis is unknown.
All heart attacks are not created equally, and that is especially true when it comes to the difference in symptoms between men and women. Knowing how to identify heart attack symptoms is critical to getting treatment quicker and saving valuable heart muscle. Dr. Tara Jarreau of Louisiana Cardiology Associates offers the following advice on recognizing heart attack symptoms.
Studies have shown there is a distinct disparity between men and women when it comes to the heart. For example, women have smaller hearts and smaller arteries than men do. This could be why the symptoms of a heart attack are different for women than men.
Led by Yang Zhou, PhD, a postdoctoral fellow in the laboratory of Li Qian, PhD, assistant professor of pathology and laboratory medicine at UNC, research published in Cell Reports suggests that one method leads to the creation of cardiomyocytes with genetic signatures that closely mimic those found in healthy adult heart muscle cells. The other reprogramming approach leads to the creation of cardiomyocytes with more embryonic cell signatures.
Metabolically, iPSC-CMs had a higher expression of glycolytic genes while iCMs had a higher expression of genes involved in fatty acid oxidation, the primary means of energy production in adult hearts.
In iPSC-CMs, heart muscle cells called sarcomeres, which give the heart a striated look, were less organized than in iCMs. The contractibility of cardiomyocytes as measured by the intake and removal of calcium was also greater in iCMs, again suggesting that iCM cells are more mature than iPSC-CM cells. 041b061a72